London, UK, 9 September 2021 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced positive high-level results from the MANDALA and DENALI Phase III trials of a new, fixed-dose combination inhaler for those who suffer from asthma. JoinAStudy.ca Investigators Dr. Syed Anees, Dr. Peter Dzongowski, Dr. Anil Gupta, Dr. Sam Henein and Dr. Sean
Arthritis is a chronic and debilitating disease identified by symptoms such as joint pain, stiffness, swelling and decreased range of motion. The two most common types of arthritis are osteoarthritis (OA) and rheumatoid arthritis (RA). It is estimated that over 4.6 million Canadians suffer from arthritis, and it is a leading cause of disability. A
Approximately 550,000 Canadians suffer from the neurodegenerative disease known as Alzheimer’s Disease, which is also the cause of 60% to 70% of cases of dementia. This disease is associated with symptoms such as memory loss, difficulty performing simple tasks, disorientation of time and space, and even sudden changes in mood or personality. It is a
